Pancreatic cancer Market, by type, by treatment, by types, Industry Trends and Analysis and Forecast to 2022

“Global Pancreatic cancer Market Research Report- Forecast To 2022”

Global Pancreatic cancer Information, by type (endocrine pancreas cancer, exocrine pancreas cancer and others), by treatment type (surgery, chemotherapy, radiation therapy and others), by end users (hospital, clinics, research institutes and others) – Forecast to 2022

Market Synopsis of Pancreatic cancer market:

Market Scenario:

Cancer starts when cells in the body begin to grow out of control. Pancreatic cancer starts when cells in the pancreas start to grow uncontrollably.  It causes Symptoms like abdominal pain, weight loss, diarrhea, and jaundice.  The tumor hinders the normal functioning of pancreas. The biggest risk factor for developing pancreatic cancer is smoking. To diagnose the cancer doctor will do a complete physical exam and history check and then blood, urine, and stool tests may be done.

Market for Pancreatic cancer is growing as there is an increase in the consumption of alcohol, smoking and change is lifestyle. The global market for Pancreatic cancer is expected to reach US$ XX by the end of the forecasted period and is expected to grow at a CAGR of XX%.

 

Key Players for Pancreatic cancer market:

  • PharmaCyte Biotech Inc. (US),
  • OncoGenex Pharmaceuticals Inc.,
  • Oncolytics Biotech (Canada),
  • DiffusionPharmaceuticals (US),
  • Polaris Pharmaceuticals, Inc.,
  • Sun BioPharma, Inc.,
  • Midatech Pharma PLC (UK)
  • others.

Request a Sample Copy @ https://www.marketresearchfuture.com/sample_request/1638

 

Segments:

Global Pancreatic cancer market has been segmented

On the basis of type which comprise of endocrine pancreas cancer, exocrine pancreas cancer and others.

On the basis of treatment type; market is segmented into; surgery, radiation therapy, chemotherapy and others.

On the basis of end users; market is segmented as; hospital, clinics, research institutes and others.

 

Taste the market data and market information presented through more than 50 market data tables and figures spread in 110 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Global Pancreatic cancer Market Research Report- Forecast To 2022

 

Request TOC @ https://www.marketresearchfuture.com/request-toc/1638

 

Study Objectives of Pancreatic cancer Market:

  • To provide detailed analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the Pancreatic cancer market
  • To provide insights about factors affecting the market growth
  • To analyze the pancreatic cancer market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
  • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
  • To provide country level analysis of the market with respect to the current market size and future prospective
  • To provide country level analysis of the market for segments by type, by treatment type, by end users and its sub-segments.
  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global pancreatic cancer market.

The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions.

 

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Related Report

Global Blood Transfusion Diagnostics Market Information by Type (Instruments, Reagents), By Application (Blood Grouping, disease Screening), By End users (Hospital, laboratories, Blood Banks, Plasma Fractionation Facilities) – Forecast to 2027.Know more about this report @ https://www.marketresearchfuture.com/reports/blood-transfusion-diagnostics-market

 

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Media Contact
Company Name: Market Research Future
Contact Person: Akash Anand
Email: akash.anand@marketresearchfuture.com
Phone: +1 646 845 9312
Address:Magarpatta Road, Hadapsar, Pune – 411028 Maharashtra, India
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/pancreatic-cancer-market

Appeal for information on missing man in Tuen Man (with photo)

Appeal for information on missing man in Tuen Man (with photo)

**************************************************************

     Police today (June 6) appealed to the public for information on a man who went missing in Tuen Mun.
      
     Cheng Chin-hung, aged 65, went missing after he was last seen in a hospital on Tsing Chung Koon Road yesterday (June 5) noon. A staff member of a hostel made a report to Police on the same day.
      
     He is about 1.55 metres tall, 50 kilograms in weight and of medium build. He has a pointed face with yellow complexion and short straight black hair. He was last seen wearing a light blue T-shirt, black sports pants, and grey sandals.
      
     Anyone who knows the whereabouts of the missing man or may have seen him is urged to contact the Regional Missing Person Unit of New Territories North on 3661 3113 or email to rmpu-ntn-1@police.gov.hk, or contact any police station.

 

Ends/Tuesday, June 6, 2017
Issued at HKT 14:05

NNNN

Photo

Cheng Chin-hung, aged 65, is about 1.55 metres tall, 50 kilograms in weight and of medium build. He has a pointed face with yellow complexion and short straight black hair. He was last seen wearing a light blue T-shirt, black sports pants, and grey sandals.

Special traffic arrangements for race meeting in Happy Valley tomorrow

Special traffic arrangements for race meeting in Happy Valley tomorrow

***********************************************************************

     Special traffic arrangements will be implemented in Happy Valley tomorrow (June 7). The arrangements will come into effect one and a half hours before the start of the first race and will last until the crowds have dispersed after the race meeting.

A. Traffic arrangements before the commencement of the first race

1. Road closure

     A section of southbound Wong Nai Chung Road between Queen’s Road East and the up ramp outside Hong Kong Jockey Club (HKJC) will be closed except for vehicles to Aberdeen Tunnel.

2. Traffic diversion

(a) A section of southbound Wong Nai Chung Road between Village Road and the up ramp outside HKJC will be re-routed one way northbound;

(b) Vehicles from eastbound Queen’s Road East heading for Wan Chai and Happy Valley will be diverted to turn left to Morrison Hill Road;

(c) Vehicular traffic on southbound Morrison Hill Road heading for Happy Valley will be diverted via Sports Road and Wong Nai Chung Road;

(d) Vehicular traffic on Queen’s Road East will be banned from turning right to Wong Nai Chung Road except for access to Aberdeen Tunnel;

(e) Vehicular traffic from Cross Harbour Tunnel heading for Queen’s Road East will be diverted via the down ramp leading from southbound Canal Road flyover to Morrison Hill Road to turn right at the junction of Wong Nai Chung Road and Queen’s Road East; and

(f) Vehicular traffic from Cross Harbour Tunnel heading for Happy Valley or Racecourse will be diverted via the down ramp leading from southbound Canal Road flyover to Canal Road East, southbound Morrison Hill Road, Sports Road and Wong Nai Chung Road.

B. Traffic arrangements during the race meeting

1. Road closure

     The following roads will be closed from 35 minutes before the start of the last race:

(a) The up ramp on Wong Nai Chung Road outside HKJC leading to Aberdeen Tunnel;

(b) A section of southbound Wong Nai Chung Road between Queen’s Road East and the up ramp leading to Aberdeen Tunnel;

(c) A section of southbound Wong Nai Chung Road between Village Road and the Public Stands of HKJC;

(d) A section of westbound Leighton Road between Wong Nai Chung Road and Canal Road East; and

(e) A section of southbound Morrison Hill Road between Leighton Road and Queen’s Road East.

     In addition, a section of southbound Wong Nai Chung Road between the up ramp leading to Aberdeen Tunnel and the Public Stands of HKJC will be closed to all vehicular traffic from about 10 minutes before the start of the last race.

2. Traffic diversion

     The following traffic arrangements will be implemented from 35 minutes before the start of the last race:

(a) Eastbound Queen’s Road East at its junction with Morrison Hill Road will be reduced to one traffic lane heading for northbound Canal Road flyover;

(b) Vehicular traffic on southbound Canal Road flyover from Cross Harbour Tunnel heading for Wan Chai will be diverted via the down ramp leading to Canal Road East to U-turn beneath Canal Road flyover onto Canal Road West towards Hennessy Road;

(c) Vehicular traffic on southbound Canal Road flyover from Cross Harbour Tunnel heading for Happy Valley will be diverted via the down ramp leading to Canal Road East, eastbound Leighton Road and Wong Nai Chung Road;

(d) Vehicular traffic on southbound Morrison Hill Road will be diverted to turn left to eastbound Leighton Road;

(e) Vehicular traffic on southbound Morrison Hill Road heading for Happy Valley will be diverted via eastbound Leighton Road and Wong Nai Chung Road; and

(f) Vehicular traffic on westbound Leighton Road will be diverted to Wong Nai Chung Road.

C. Suspension of parking spaces

     Parking spaces on Wong Nai Chung Road will be suspended from 11am to 7pm during day racing, from 4.30pm to 11.59pm during evening racing, and from 5pm to 11.59pm during night racing.

D. Learner drivers prohibition

     Learner drivers will be prohibited to turn left from Caroline Hill Road to Leighton Road between one and a half hours before the start of the first race and one hour after the last race. In addition, learner drivers will be prohibited from accessing the following roads within the above period of time:

(a) A section of Shan Kwong Road between Yik Yam Street and Wong Nai Chung Road;

(b) A section of Village Road between its upper and lower junctions with Shan Kwong Road;

(c) A section of Percival Street between Hennessy Road and Leighton Road;

(d) Canal Road East; and

(e) The service road leading from Gloucester Road to Canal Road flyover.

     Any vehicles found illegally parked within the precincts of the above affected areas will be towed away without prior notice.

     Actual implementation of road closure and traffic diversion will be made by the Police at the time depending on traffic conditions in the areas. Motorists should exercise tolerance and patience, and follow the instructions of Police on site.

 

Ends/Tuesday, June 6, 2017
Issued at HKT 15:21

NNNN

Toronto ETO hosts official gala dinner in celebration of 20th anniversary of HKSAR in Toronto (with photos)

     The Hong Kong Economic and Trade Office (Toronto) (Toronto ETO) held an official gala dinner in Toronto, Canada, in collaboration with the Hong Kong Tourism Board (HKTB) on June 5 (Toronto time) in celebration of the 20th anniversary of the establishment of the Hong Kong Special Administrative Region (HKSAR). More than 200 guests attended the dinner, including the Consul General of the People’s Republic of China in Toronto, Mr He Wei; Member of Parliament Mr Michael Chong; the Mayor of the City of Markham, Mr Frank Scarpitti; the Mayor of Mississauga, Ms Bonnie Crombie; and the Executive Director of the HKTB, Mr Anthony Lau. 

     In delivering the welcome remarks at the dinner, the Director of the Toronto ETO, Miss Kathy Chan, said that the HKSAR 20th anniversary is a special occasion and a major milestone in Hong Kong’s development. “Over the past 20 years, the real Gross Domestic Product of Hong Kong has achieved a cumulative growth of more than 80 per cent. The number of regional headquarters and offices set up by overseas and Mainland corporations in Hong Kong has increased by 50 per cent. The amount of foreign direct investment stock has expanded by 6.5 times,” Miss Chan said.

     With a strong dedication to building a fair and just society for all, the HKSAR Government has allocated substantial resources to care for the needy to ensure that they can also enjoy the fruits of economic advancement. At the same time, the Government has also invested heavily in education to nurture talents so as to maintain the competitiveness of Hong Kong. Miss Chan noted that over the past five years alone, recurrent expenditures on social welfare and education have increased by about 70 per cent and 30 per cent respectively.

     The theme of the HKSAR 20th anniversary celebrations is “Together‧Progress‧ Opportunity”. “The past 20 years have not always been smooth sailing for Hong Kong. We have faced many challenges, such as Severe Acute Respiratory Syndrome (SARS) in 2003 and the global financial crisis in 2008. We could not have overcome the uphill battles without Hong Kong people staying together,” Miss Chan said.

     “More importantly, we would not have been able to prevail at difficult times without the staunch support of the Central Government,” Miss Chan added. She cited the measures rolled out at those crucial moments by the Central Government including the signing of the Mainland and Hong Kong Closer Economic Partnership Arrangement in 2003 and the usage of Hong Kong as the launch pad of Mainland China’s financial market liberalisation measures since 2008 under the “one country, two systems” arrangement. 

     Despite the remarkable economic and social achievements in the past 20 years, Miss Chan said that to sustain progress it is important for Hong Kong to press ahead with big projects, such as those in infrastructure, education and healthcare development.

     On infrastructure, Miss Chan said that the Hong Kong-Zhuhai-Macao Bridge is targeted for completion by the end of this year to provide a direct land link between Hong Kong and the west coast of the Pearl River Delta. Hong Kong also aims to commission service of the Hong Kong section of the Guangzhou-Shenzhen-Hong Kong Express Rail Link in the third quarter of next year. At the same time, Hong Kong has embarked on construction works for the third runway of the Hong Kong International Airport in order to strengthen its position as a regional aviation hub.

     In terms of improving the well-being of the community, the HKSAR Government has earmarked a sum of $200 billion for a 10-year hospital development plan. The Government will also devote extra resources to better education for the next generation and vigorously attract talents from all over the world, including Canada, to develop careers in Hong Kong.

     Miss Chan remarked that in future Hong Kong will continue to seize every opportunity to grow with its sound fundamentals, such as the rule of law, clean and efficient government, low taxes, business-friendly practices with a level playing field, and world-class infrastructure. She said she was confident that Hong Kong would be able to achieve another 20 years of remarkable progress and continue to shine on the international stage as Asia’s world city.

     To showcase the long-standing friendship and close interactions between Canada and Hong Kong, the Toronto ETO collaborated with the HKTB to engage renowned Hong Kong culinary master and Executive Chef of VEA Restaurant and Lounge in Hong Kong Mr Vicky Cheng and the Executive Chef of Fairmont Royal York Hotel in Toronto, Mr Robert Mills to jointly present an exquisite dinner menu that incorporated and blended the essence of Hong Kong and Canadian cuisines.

     Before the Gala came to a close, the guests were treated to an exclusive cultural performance staged by Hong Kong and Canadian performers. Young talented artists of the Hong Kong Academy for Performing Arts put on an unforgettable Cantonese opera performance of the noted excerpt “Eight Divinities Crossing the Sea” together with the starlets of the Starlight Chinese Opera Performing Arts Centre in Toronto. Cantonese opera performance was picked because it is a comprehensive and sophisticated art form which was inscribed in United Nations Educational, Scientific and Cultural Organization’s Representative List of the Intangible Cultural Heritage of Humanity in 2009. Hong Kong has been an important place for the succession and development of Cantonese opera, and is keen on promoting it and sharing it with wider communities including friends in Canada.

Hong Kong Monetary Authority Exchange Fund Bills tender results

Hong Kong Monetary Authority Exchange Fund Bills tender results

***************************************************************

The following is issued on behalf of the Hong Kong Monetary Authority:

Hong Kong Monetary Authority Exchange Fund Bills tender results
***********************************

Tender date : June 6, 2017
Paper on offer : EF Bills
Issue number : Q1723
Issue date : June 7, 2017
Maturity date : September 6, 2017
Amount applied : HK$92,785 MN
Amount allotted : HK$39,980 MN
Average yield accepted : 0.32 PCT
Highest yield accepted : 0.32 PCT
Pro rata ratio : About 52 PCT
Average tender yield : 0.33 PCT
****************************
Tender date : June 6, 2017
Paper on offer : EF Bills
Issue number : H1752
Issue date : June 7, 2017
Maturity date : December 6, 2017
Amount applied : HK$54,185 MN
Amount allotted : HK$15,000 MN
Average yield accepted : 0.41 PCT
Highest yield accepted : 0.42 PCT
Pro rata ratio : About 45 PCT
Average tender yield : 0.45 PCT


———————————————————
     Hong Kong Monetary Authority tenders to be held in the week beginning June 12, 2017:
 

Tender date : June 13, 2017
Paper on offer : EF Bills
Issue number : Q1724
Issue date : June 14, 2017
Maturity date : September 13, 2017
Tenor : 91 Days
Amount on offer : HK$36,176 MN
****************************
Tender date : June 13, 2017
Paper on offer : EF Bills
Issue number : H1753
Issue date : June 14, 2017
Maturity date : December 13, 2017
Tenor : 182 Days
Amount on offer : HK$9,000 MN
****************************
Tender date : June 13, 2017
Paper on offer : EF Bills
Issue number : Y1790
Issue date : June 14, 2017
Maturity date : June 13, 2018
Tenor : 364 Days
Amount on offer : HK$3,000 MN
****************************
Tender date : June 16, 2017
Paper on offer : EF Bills
Issue number : M1703
Issue date : June 19, 2017
Maturity date : July 19, 2017
Tenor : 30 Days
Amount on offer : HK$2,200 MN

 

Ends/Tuesday, June 6, 2017
Issued at HKT 16:10

NNNN

Three importers convicted for illegal import of hazardous e-waste

Three importers convicted for illegal import of hazardous e-waste

*****************************************************************

     Three importers who illegally imported hazardous electronic waste (e-waste) from Malaysia, the Democratic Republic of the Congo and the United Arab Emirates were convicted and fined a total of $46,000 by the Fanling Magistrates’ Courts today (June 6) for contravening the Waste Disposal Ordinance (WDO).
 
     In collaboration with the Customs and Excise Department, the Environmental Protection Department (EPD) intercepted four imported containers at the Kwai Chung Container Terminals from September to November last year and found hazardous e-waste comprising waste printed circuit boards inside them. They were intended for import into Hong Kong or transshipment to the Mainland. These four intercepted containers were immediately returned to the states of origin and the EPD also notified the relevant local enforcement authorities. The total market value of the intercepted hazardous e-waste was about $470,000.
 
     The EPD spokesman reiterated that the intercepted waste printed circuit boards are classified as hazardous e-waste, which contains heavy metals (such as mercury, lead and nickel) and other toxic chemicals. Improper handling of such waste can cause harm to the environment and public health. The EPD strictly controls the import and export of hazardous waste according to the WDO and is committed to combating the illegal import of hazardous waste into Hong Kong. All illegally imported containers that are intercepted will be returned to the states of origin following international practice and the offenders will be prosecuted.
 
     The spokesman reminded importers of the waste recycling trade not to illegally import hazardous waste into Hong Kong for whatever purpose, including import into or transshipment through Hong Kong. In accordance with the WDO, it is an offence for anyone to import (including transshipment) or export hazardous waste without valid permits. First-time offenders are liable to a maximum fine of $200,000 and six months’ imprisonment. Repeat offenders are liable to a maximum fine of $500,000 and two years’ imprisonment.

 

Ends/Tuesday, June 6, 2017
Issued at HKT 16:12

NNNN

DIGITAL ECONOMY ASIA IS BOOSTING BUSINESS CREDIBILITY OF ITS CLIENTS VIA INTERNATIONAL MEDIA COVERAGE LIKE NEVER BEFORE

Digital Economy Asia has announced that it will be helping the businesses based primarily in South East Asia to boost their business credibility through exclusive international media coverage. Digital Economy Asia is an agency specialized in helping businesses accelerate their growth and production capacity. In addition, the agency is extending its offers to small and medium enterprises to be featured on International Media to boost the credibility as well as the profitability of their sales.

“Business Credibility is highly important in the industry because it is directly proportional to the number of sales generated by that particular business in the industry.” Said Sahlan while talking about the services offered by the agency. “We are proudly helping our clients from all across the Asian continent to boost their business while getting featured on international media in order to increase and multiply their credibility to the new heights,” he added.

Digital Economy Asia comprises of expert digital business strategists who are currently focusing on South East Asia as their focal point. Headquartered in the heart of Asia, Malaysia, the agency is helping new and existing businesses to promote their brands and sales to the new elevations. In addition, these expert strategists provide a second opinion to entrepreneurs upon building a strong foundation for the growth of their business. Moreover, the candid advice by these industry experts also help the business owners to boost their visibility globally also through the agency’s ever expanding international media network.

Business Credibility is highly important because without it, the number of sales and production drops drastically. Therefore, the services offered by the company are intended to help the business owners in making informed decisions and proceed to their next steps with utmost confidence. In addition, the agency also offers quick email support on 24 hours in which the expert representatives get back to the client regarding the relevant information regarding the consultation services offered by the company. Furthermore, to guarantee satisfaction of clients, the agency offers its services with 30 day delivery or full money back guarantee.

The primary services offered by the Digital Economy Asia cover vast aspects of market research and market strategy. The experienced analysts working at the agency provide a secondary insights for market research and marketing reports for businesses with candid research, facts and figures. Moreover, the services offered in Market Research provide detailed trends and insights of the market along with comprehensive Marketing Strategy Reports. These reports include positioning, branding and marketing itself to increase business credibility.

For more information and to boost the credibility of your business today, please visit:

www.DigitalEconomy.Asia

Media Contact
Company Name: Digital Economy Asia
Contact Person: Media Manager
Email: editor@in2town.co.uk
Country: India
Website: http://www.DigitalEconomy.Asia

Global Market Study On Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3. 5. 1. 98) – Pipeline Review, H1 2017

Orbisreserach.Com Adds “H1 Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3. 5. 1. 98) Market Pipeline Review 2017 Trend Analysis Report Report” To Its Research Database

Description:

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies. The latest report Histone Deacetylase 8 – Pipeline Review, H1 2017, outlays comprehensive information on the Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Request a sample of this report @ www.orbisresearch.com/contacts/request-sample/310028 .

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) – Histone deacetylase 8 is an enzyme encoded by the HDAC8 gene. It is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. The molecules developed by companies in Phase III, Preclinical, Discovery and Unknown stages are 1, 5, 1 and 1 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Infectious Disease and Musculoskeletal Disorders which include indications Breast Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Adenoid Cystic Carcinoma (ACC), B-Cell Non-Hodgkin Lymphoma, Bone Disorders, Brain Cancer, Cognitive Disorders, Colon Cancer, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Liver Cancer, Liver Fibrosis, Lung Cancer, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Neurodegenerative Diseases, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Prostate Cancer, Renal Cell Carcinoma and T-Cell Leukemia.

Furthermore, this report also reviews key players involved in Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Browse the full report @ www.orbisresearch.com/reports/index/histone-deacetylase-8… .

Scope
– The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)
– The report reviews Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)targeted therapeutics and enlists all their major and minor projects
– The report assesses Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics
Purchase a copy of this report @ www.orbisresearch.com/contact/purchase/310028 .

Reasons to buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned
Chipscreen Biosciences Ltd
HitGen LTD
NatureWise Biotech & Medicals Corp
Sigma-Tau SpA
Zhejiang Hisun Pharmaceutical Co Ltd

For any enquires before buying, connect with us @ enquiry@orbisresearch.com

About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
For more information contact sales@orbisresearch.com

This release was published on openPR.

2017 Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) Industry Survey, Market Size, Competitive Trends and Forecasts : Orbis Research

OrbisResearch.com has published new research report on „H1 Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) Market Pipeline Review 2017 Trend Analysis Report ” to its database

Description:

According to the recently published report ‚Transforming Growth Factor Beta 2 – Pipeline Review, H1 2017’; Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

Request a sample of this report @ www.orbisresearch.com/contacts/request-sample/310029 .

Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) – Transforming growth factor beta 2 (TGF-β2) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB2 gene. It regulates proliferation, differentiation, adhesion and migration. It has suppressive effects on interleukin-2 dependent T-cell growth.

The report ‚Transforming Growth Factor Beta 2 – Pipeline Review, H1 2017’ outlays comprehensive information on the Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Browse the full report @ www.orbisresearch.com/reports/index/transforming-growth-f… .

It also reviews key players involved in Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 1 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecule, respectively. Report covers products from therapy areas Oncology, Ophthalmology, Dermatology, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Musculoskeletal Disorders and Respiratory which include indications Glioblastoma Multiforme (GBM), Open-Angle Glaucoma, Choroidal Neovascularization, Fibrosis, Head And Neck Cancer, Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Liver Fibrosis, Melanoma, Metastatic Breast Cancer, Metastatic Lung Cancer, Non-Small Cell Lung Cancer, Osteogenesis Imperfecta, Pancreatic Cancer, Proliferative Vitreoretinopathy (PVR) and Scar.

Scope
– The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2)
– The report reviews Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2)targeted therapeutics and enlists all their major and minor projects
– The report assesses Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics

Purchase a copy of this report @ www.orbisresearch.com/contact/purchase/310029 .

Reasons to buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2)development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned
Autotelic Inc
Genzyme Corp
Isarna Therapeutics GmbH
Novartis AG

Purchase a copy of this report @ www.orbisresearch.com/contact/purchase/310029 .

For any enquires before buying, connect with us @ enquiry@orbisresearch.com

About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients

Contact Us:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
For more information contact sales@orbisresearch.com

This release was published on openPR.

Airbus organises start-up event in Singapore

Airbus’ first start-up event held over the weekend of 2-4 June in Singapore, attracted around 80 participants from the region, competing on aerospace concepts that could lead to greater innovation in the industry.

Held in partnership with SGInnovate, a Singapore government agency supporting entrepreneurial start-ups, the participants worked day and night to fine-tune their ideas.

The event was inspired by the Singapore government’s Smart Nation initiative, which aims to identify solutions that use connectivity and technology to improve the life of ordinary people, particularly in areas such as transportation, infrastructure and security.

Each team had three minutes to pitch their plans to a panel of judges, which included representatives from Airbus, Singapore’s Economic Development Board (EDB), the Defence Science and Technology Agency (DSTA) and the Singapore Space and Technology Association (SSTA).

Winning the top prize of $5,000 and an A380 full flight simulator experience was Team R.E.D., postgraduate students from Malaysia’s University Putra Malaysia and University of Malaya, which came up with an innovative first responder application for emergency and disaster support. Other impressive ideas included one that uses IOT sensors and satellite data for early detection and management of oil spills, and another that leverages a network of drones and satellite sensors to provide an efficient delivery solution.

Guillaume Faury, CEO of Airbus Helicopters, awarded the prizes to the winning teams.

Mr Faury said: “Airbus is making multiple efforts to deepen its engagement with the start-up ecosystem, and this is part of a broader global effort to increase the speed of innovation in the aerospace industry. This start-up event allows Airbus to tap on the vibrant start-up eco-system in Singapore and the region. We met some talented developers with very interesting ideas, and we are confident that some of these can contribute to Singapore’s Smart Nation initiative.”

“This start-up event is a great initiative by Airbus, in addition to several technology development projects it is already undertaking here. It reinforces the strong partnership between Airbus and Singapore. The event will give Singapore’s growing start-up ecosystem a boost, and could pave the way towards new business opportunities and partnerships between Airbus and young companies here and in the region,” said Lim Kok Kiang, Assistant Managing Director, EDB.

Airbus is involved in several innovation projects in Singapore. These include the “Hangar of the Future”, which aims to develop new digital solutions for maintenance, repair and overhaul (MRO) providers, and the Skyways unmanned parcel delivery system.